ArticleThe oncologist2024
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.
Article in The oncologist, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07689812 (A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Continuous Immune-Checkpoint Inhibitor), which is not on this map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Continuous Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced/Metastatic Solid Tumors
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Serial ctDNA dynamics predict clinical outcomes in metastatic and locally advanced PDAC: a systematic review.Frontiers in oncology · 2026Pooled it
- Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: A Phase II Study.Cancer medicine · 2025Trial
- Site-specific limitations of ctDNA in PDAC surveillance: imaging detects pulmonary and local recurrence missed by liquid biopsy.Abdominal radiology (New York) · 2026Article
- Real-world analysis of ctDNA and other biomarkers in patients with curatively resected stage I-III biliary tract cancer.ESMO gastrointestinal oncology · 2026Article
- From clinical insight to trial design: advancing circulating tumor DNA-informed care in pancreatic cancer.Journal of gastrointestinal oncology · 2026Review
- Liquid Biopsy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis.Annals of surgical oncology · 2026Article
- Development and Validation of Nomograms for Predicting Overall Survival and Recurrence After Upfront Pancreatic Resection for Ductal Adenocarcinoma: A Single-Institution Analysis of 2958 Patients.Annals of surgical oncology · 2026Article
- Circulating tumor DNA in gastrointestinal cancers: promise, pitfalls, and the path forward.EClinicalMedicine · 2026Review
- The role of the WD40-repeat protein family in cancer.Molecular cancer · 2026Review
- Review
- Review
- Liquid Biopsy Frontiers in Pancreatic Cancer: Insights from Circulating Cell-Free Nucleic Acids.Cells · 2026Review
- Circulating Tumor DNA as a Biomarker in Pancreatic Cancer: Clinical Applications and Challenges.Clinical and translational gastroenterology · 2026Review
- Review
- Review
- New implications from long-term outcomes of perioperative therapy in resectable pancreatic cancer.British journal of cancer · 2026Review
- Multi-Institutional Study Evaluating the Role of Early Circulating Tumor DNA Dynamics During Treatment With Immune Checkpoint Inhibitors in Patients With Advanced-Stage Melanoma.JCO precision oncology · 2026Article
- Limited benefits of neoadjuvant therapy on R0 resection rate and overall survival in patients with resectable or locally advanced PDAC in randomized controlled trials.Frontiers in medicine · 2026Review
- Excellent Survival Outcome in a Patient Receiving NALIRIFOX for Metastatic Pancreatic Adenocarcinoma: A Case Report.Oncology research · 2026Article
- Personalized tumor-informed circulating tumor DNA monitoring for early detection of recurrence in postoperative pancreatic cancer.Frontiers in oncology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
28 authors.
Funding
Abstract
introductionPersonalized and tumor-informed circulating tumor DNA (ctDNA) testing is feasible and allows for molecular residual disease (MRD) identification in patients with pancreatic ductal adenocarcinoma (PDAC).
methodsIn this retrospective analysis of commercial cases from multiple US institutions, personalized, tumor-informed, whole-exome sequenced, and germline-controlled ctDNA levels were quantified and analyzed in patients with PDAC. Plasma samples (n = 1329) from 298 clinically validated patients were collected at diagnosis, perioperatively (MRD-window; within 2-12 weeks after surgery, before therapy), and during surveillance (>12 weeks post-surgery if no ACT or starting 4 weeks post-ACT) from November 2019 to March 2023.
resultsOf the initially diagnosed patients with stages I-III PDAC who went for resection, the median follow-up time from surgery was 13 months (range 0.1-214). Positive ctDNA detection rates were 29% (29/100) and 29.6% (45/152) during the MRD and surveillance windows, respectively. Positive ctDNA detection was significantly associated with shorter DFS within the MRD window (median DFS of 6.37 months for ctDNA-positive vs 33.31 months for ctDNA-negative patients; HR: 5.45, P < .0001) as well as during the surveillance period (median DFS: 11.40 months for ctDNA-positive vs NR for ctDNA-negative; HR: 12.38, P < .0001). Additionally, DFS was significantly better with KRAS wildtype status followed by KRASG12R (HR: 0.99, P = .97), KRASG12D (HR: 1.42, P = .194), and worse with KRASG12V (HR: 2.19, P = .002) status. In multivariate analysis, ctDNA detection at surveillance was found to be the most significant prognostic factor for recurrence (HR: 24.28, P < .001).
conclusionsPerioperative tumor-informed ctDNA detection in PDAC is feasible across all stages and is associated with patient survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.